March 2005 PBAC Outcomes - Deferrals

PDF Printable version this page (PDF 19 KB)

Table containing Deferrals made by the Pharmaceutical Benefits Advisory Committee in March 2005
Drug and form	Drug use and type	Listing requested by Sponsor	PBAC outcome and comment
LETROZOLE tablet 2.5 mg, Femara® Novartis Pharmaceuticals Australia Pty Ltd Major submission	Antineoplastic agent	Extend the restricted benefit listing for treatment of early-stage hormone-dependent breast cancer in post-menopausal women who have completed standard adjuvant tamoxifen therapy.	The PBAC deferred the submission to seek clarification of the incremental cost-effectiveness ratios based on distant recurrence alone.
	Antineoplastic agent	Sponsor’s comments	The sponsor will be responding to the PBAC request and refers you to its own website for further information. Weblink:http://www.novartis.com.au
PIOGLITAZONE tablet 15 mg, 30 mg and 45 mg, Actos® Eli Lilly Australia Pty Ltd Minor submission	Antidiabetic drug	For the treatment of type 2 diabetes in indigenous Australians. Unrestricted listing for this patient group	The PBAC deferred consideration of this matter until a formal process for provision of pharmaceuticals to the indigenous population under the 2004-05 Budget measure has been determined by the Department.
	Antidiabetic drug	Sponsor’s comments	The sponsor needs to clarify this decision with the PBAC.
ROSIGLITAZONE tablet, 4 mg and 8 mg, Avandia® GlaxoSmithKline Australia Pty Ltd Minor submission	Antidiabetic drug	For the treatment of type 2 diabetes in indigenous Australians. Unrestricted listing for this patient group	The PBAC deferred consideration of this matter until a formal process for provision of pharmaceuticals to the indigenous population under the 2004-05 Budget measure has been determined by the Department.
	Antidiabetic drug	Sponsor’s comments	The sponsor has no commen